Richard Cottiero, MD
Nephrology · Las Vegas, NVNPI 1295733988
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $167,728 of the $219,937 with a category attached, or 76.3%. 32 manufacturers reported payments, led by AstraZeneca at 27.0% of the total. Reporting peaked in 2021 at $53,142 and has fallen 65.7% since, to $18,230 in 2025. Among nephrology clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 671 payments — averaging $327.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$59K
- Travere Therapeutics, Inc.$49K
- Akebia Therapeutics Inc$35K
- Bayer$33K
- Vifor Pharma, Inc.$19K
- Otsuka America Pharmaceutical, Inc.$14K
- plus $10K from 26 others
What the payments were for
- Consulting fees$15,4407%
- Speaking & faculty fees$167,72876%
- Travel & lodging$15,7997%
- Food & beverage$20,3389%
- Education$6320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 138 | $59,391 |
| Travere Therapeutics, Inc. | 93 | $49,370 |
| Akebia Therapeutics Inc | 69 | $35,085 |
| Bayer | 53 | $33,175 |
| Vifor Pharma, Inc. | 74 | $19,103 |
| Otsuka America Pharmaceutical, Inc. | 59 | $13,985 |
| Amgen(2 entities) | 46 | $4,649 |
| Johnson & Johnson | 15 | $917 |
| Novartis | 8 | $593 |
| Boehringer Ingelheim | 9 | $487 |
| Aurinia Pharma U.S., Inc. | 14 | $443 |
| GSK | 12 | $386 |
| Fresenius USA Marketing, Inc. | 11 | $338 |
| OPKO Pharmaceuticals, LLC | 21 | $321 |
| Calliditas Therapeutics US Inc. | 5 | $290 |
| Mallinckrodt Hospital Products Inc. | 5 | $223 |
| Daiichi Sankyo Inc. | 5 | $216 |
| ANI Pharmaceuticals, Inc. | 6 | $156 |
| Novo Nordisk | 2 | $131 |
| Arbor Pharmaceuticals, Inc. | 7 | $128 |
| Apellis Pharmaceuticals, Inc. | 1 | $125 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $77 |
| Pfizer | 1 | $66 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $42 |
| Ultragenyx Pharmaceutical Inc. | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
| Lilly USA, LLC | 2 | $38 |
| Strongbridge US Inc. | 3 | $38 |
| Regeneron Healthcare Solutions, Inc. | 2 | $23 |
| Kyowa Kirin, Inc. | 1 | $23 |
| Mallinckrodt Enterprises LLC | 1 | $22 |
| Shire North American Group Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$219,937 in reported general payments places this provider in the 95th percentile of 125 nephrology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 57 | $39,957 |
| FarxigaDapagliflozin Propanediol | 13 | $19,758 |
| KerendiaFinerenone | 11 | $6,996 |
| Calcitriol | 60 | $929 |
| Amlodipine Besylate | 86 | $393 |
| Losartan Potassium | 48 | $264 |
| Hydralazine Hcl | 14 | $183 |
| Chlorthalidone | 15 | $146 |
| Lisinopril | 35 | $118 |
| Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid | 12 | $51 |
| Ciprofloxacin Hcl | 14 | $48 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $487 | $39,95757 claims |
| AstraZenecaFarxiga | $59,391 | $19,75813 claims |
| BayerKerendia | $33,175 | $6,99611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 125 nephrology providers in Nevada.
Other nephrology in Las Vegas
- Samuel KantorLas Vegas$319K
- Mark VishnepolskyLas Vegas$68K
- Baishali NairLas Vegas$12K
- Gene OngLas Vegas$11K
- Jeffrey RyuLas Vegas$9K
- Luana PillonLas Vegas$9K
- Lawrence LehrnerLas Vegas$8K
- Hassan OsmanLas Vegas$8K
- Marwan TakieddineLas Vegas$8K
- Prateek SangheraLas Vegas$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.